HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): George L. Hicks, Jr. Scott S. Stewart James A. DeWeese Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hicks, G. L. Articles by DeWeese, J. A. Search for Related Content PubMed PubMed Citation Articles by Hicks, G. L., Jr. Articles by DeWeese, J. A.

Ann Thorac Surg 1985;39:422-425
© 1985 The Society of Thoracic Surgeons

---

Articles

Platelet Inhibitors and Hydroxyethyl Starch: Safe and Cost-Effective Interventions in Coronary Artery Surgery

From the Department of Surgery, University of Rochester Medical Center, Rochester, NY

Accepted for publication August 1, 1984.

^* Address reprint requests to Dr. Hicks, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642

This study evaluated the cost-effectiveness and clinical safety of utilizing hetastarch in pump prime solutions and for colloid replacement postoperatively in conjunction with the platelet inhibitors, aspirin and Persantine (dipyridamole). Sixty-four adult patients undergoing a coronary artery bypass operation were divided into two groups. Group 1 (N = 32) received only Persantine (75 mg three times a day) on the day prior to operation. Group 2 (N = 32) received the same Persantine dose plus aspirin (325 mg). In both groups, aspirin and Persantine were continued postoperatively and hetastarch was used as the colloid of choice. All patients were evaluated for blood loss, coagulation profiles, cost of blood and colloid replacement, and clinical course.

Group 2 patients demonstrated significantly greater blood loss (p < 0.05) but the same postoperative coagulation profiles as Group 1. The transfusion requirement (3.6 units versus 1.3 units) and cost basis ($252 versus $91) for patient care were higher in Group 2. Hetastarch had no effect on blood loss and was not associated with any adverse clinical reactions. Annual institutional savings based on utilization of hetastarch were calculated at $33,500 to $40,500 per 500 patients.

We conclude that preoperative administration of aspirin (325 mg) is associated with increased perioperative blood loss and higher patient costs, two variables not demonstrable with Persantine only. Use of hetastarch combined with postoperative platelet inhibition was clinically safe and was a cost-effective method of colloid replacement.